

MEDICAL POLICY



SUBJECT: ANTICOAGULATION TESTING	EFFECTIVE DATE: 06/16/11
POLICY NUMBER: 2.02.40	REVISED DATE: 06/21/12, 06/20/13, 07/17/14, 06/18/15,
CATEGORY: Technology Assessment	07/21/16, 07/20/17, 08/16/18
PAGE: 1 OF: 4	

- *If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.*
- *If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.*
- *If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.*

POLICY STATEMENT:

Based upon our criteria and assessment of the peer-reviewed literature, anticoagulation testing is considered **investigational** in the evaluation for Antiphospholipid Syndrome.

POLICY GUIDELINES:

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Antiprothrombin antibodies are members of the ill-defined, heterogeneous family of antiphospholipid antibodies, whose persistent presence in association with thromboembolic complications, recurrent miscarriage, or immune thrombocytopenia defines the antiphospholipid syndrome (APS). According to the Sapporo definition, established by an international panel of experts (Sapporo, Japan, 1999), the diagnosis of APS requires the combination of at least one clinical criterion and at least one positive test for antiphospholipid-protein antibody (aPL) confirmed at least 6-12 weeks apart. Clinical criteria include peripheral deep venous thrombosis (DVT), pulmonary embolism (PE), and/or arterial thrombotic events, which may be accompanied by thrombocytopenia and livedo reticularis. Antiphospholipid-protein antibodies include the lupus anticoagulant antibody (LA), anticardiolipin (aCL) antibodies, or anti-beta-2 glycoprotein 1 (β 2GP1) antibodies. Antiprothrombin antibody is another aPL that has been explored as a possible autoantibody associated with APS. Antiprothrombin antibodies are commonly detected by ELISA, using irradiated plates (aPT) or in complex with phosphatidylserine (aPS-PT). However the precise clinical significance of antiprothrombin antibodies has not been determined.

RATIONALE:

The American College of Obstetricians and Gynecologists (ACOG 2011) state that only three antiphospholipid antibodies - lupus anticoagulant, anticardiolipin, and anti- β 2-glycoprotein I- can be used to establish the diagnosis of APS. Results from other antiphospholipid antibodies assays do little to improve the accuracy of the diagnosis of APS and testing for such antibodies is not recommended. Miyaki et al. (2006), reported recommendations from the Eleventh International Congress on antiphospholipid antibodies for revisions to the international classification criteria for APS (Sapporo criteria). The authors found data on the clinical associations of antiprothrombin antibody are contradictory, and they imply low specificity of these antibodies for APS diagnosis (Evidence Level II). A systematic review on antiprothrombin antibodies and risk of thrombosis in APS failed to reveal an association, irrespective of isotype, site and type of event, or presence of SLE. The committee considers that the inclusion of antiprothrombin antibodies in the classification criteria for APS is premature. A systematic review by Galli et al. (2003) found no clear association with thrombosis for antiprothrombin antibodies, irrespective of isotype, site and type of event, and systemic lupus erythematosus. Therefore any increase of risk of thrombosis beyond what is predicted by lupus anticoagulants and anticardiolipin antibodies has still to be defined and their utility in clinical practice remains to be established.

SUBJECT: ANTICOAGULATION TESTING	EFFECTIVE DATE: 06/16/11
POLICY NUMBER: 2.02.40	REVISED DATE: 06/21/12, 06/20/13, 07/17/14, 06/18/15,
CATEGORY: Technology Assessment	07/21/16, 07/20/17, 08/16/18
	PAGE: 2 OF: 4

CODES: Number Description

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT: 86849 Unlisted immunology procedure

Copyright © 2018 American Medical Association, Chicago, IL

HCPCS: No specific code(s)

ICD10: D59.0 Drug-induced autoimmune hemolytic anemia
D59.1 Other autoimmune hemolytic anemias
D68.311 Acquired hemophilia
D68.312 Antiphospholipid antibody with hemorrhagic disorder
D68.318 Other hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors
D69.6 Thrombocytopenia, unspecified
I74.01-I74.09 Embolism and thrombosis of abdominal aorta (code range)
I74.10-I74.19 Embolism and thrombosis of unspecified parts of aorta (code range)
I77.6 Arteritis, unspecified
I82.0 Budd-Chiari syndrome
I82.1 Thrombophlebitis migrans
I82.210-I82.499 Embolism and thrombosis of vena cava and other thoracic veins, renal vein, and of deep veins of lower extremity (code range)
I82.4Y1-I82.4Y9 Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity (code range)
I82.4Z1-I82.4Z9 Acute embolism and thrombosis of unspecified deep veins of distal lower extremity (code range)
I82.501-I82.599 Chronic embolism and thrombosis of deep veins of lower extremity (code range)
I82.5Y1-I82.5Y9 Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity (code range)
I82.5Z1-I82.5Z9 Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity (code range)
I82.601-I82.629 Acute embolism and thrombosis of deep veins of upper extremity (code range)
I82.701-I82.729 Chronic embolism and thrombosis of veins of upper extremity (code range)
I82.811-I82.91 Embolism and thrombosis of other specified veins or unspecified veins (code range)
I82.A11-I82.A29 Embolism and thrombosis of axillary vein (code range)
I82.B11-I82.B29 Embolism and thrombosis of subclavian vein (code range)

SUBJECT: ANTICOAGULATION TESTING	EFFECTIVE DATE: 06/16/11
POLICY NUMBER: 2.02.40	REVISED DATE: 06/21/12, 06/20/13, 07/17/14, 06/18/15,
CATEGORY: Technology Assessment	07/21/16, 07/20/17, 08/16/18
	PAGE: 3 OF: 4

I82.C11-I82.C29	Embolism and thrombosis of internal jugular vein (code range)
O09.291-O09.299	Supervision of pregnancy with other poor reproductive or obstetric history (code range)
O10.011-O10.93	Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (code range)
O11.1-O11.9	Pre-existing hypertension with pre-eclampsia (code range)
O26.20-O26.23	Pregnancy care for patient with recurrent pregnancy loss (code range)
P55.0-P55.9	Hemolytic disease of newborn (code range)
P56.0-P56.99	Hydrops fetalis due to hemolytic disease (code range)
P57.0	Kernicterus due to isoimmunization
Z86.718	Personal history of other venous thrombosis and embolism

REFERENCES:

*American College of Obstetricians and Gynecologists (ACOG). Antiphospholipid syndrome. ACOG Practice Bulletin No 132. Obstet Gynecol 2012 Dec;120(6):1514-21.

Arachchilage DR and Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017 Jul;178(2):181-195.

*Atsumi T, et al. Antiprothrombin antibody: why do we need more assays? Lupus 2010 Apr;19(4):436-9.

Bertolaccini ML and Sanna G. Recent advances in understanding antiphospholipid syndrome. F1000Res. 2016; 5: 2908.

*Bertolaccini ML, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014 Sep;13(9):917-30.

*Cervera R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome. Autoimmun Rev 2014 Jul;13(7):699-707.

Cervera R. Antiphospholipid syndrome. Thromb Res 2017 Mar;151Suppl 1:S43-S47.

Cervera R, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicenter prospective study of 1000 patients. Ann Rheum Dis 2015 Jun;74(6):1011-8.

Chaturvedi S, et al. Recent advances in the antiphospholipid antibody syndrome. Curr Opin Hematol 2014 Sep;21(5):371-9.

Chighizola CB, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus 2015 Aug;24(9):980-4.

DeJesus GR, et al. 14th International Congress on Antiphospholipid antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014 Aug;13(8):795-813.

*Devreese KM. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 2012 Oct;130 Suppl1:S37-40.

D'Ippolito S, et al. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 2014 Sep;13(9):901-8.

Favalora EJ, et al. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. Pathology 2014 Oct;46(6):481-95.

Favaloro EJ. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Hematol 2013 Jun;35(3):269-74.

SUBJECT: ANTICOAGULATION TESTING	EFFECTIVE DATE: 06/16/11
POLICY NUMBER: 2.02.40	REVISED DATE: 06/21/12, 06/20/13, 07/17/14, 06/18/15,
CATEGORY: Technology Assessment	07/21/16, 07/20/17, 08/16/18
	PAGE: 4 OF: 4

*Favaloro EJ, et al. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011 Mar;49(3):447-41.

Gabbay-Benziv R, et al. Antiphospholipid syndrome characteristics and adverse pregnancy outcomes after 20 weeks of pregnancy. Int J Gynaecol Obstet 2018 Apr 20 [Epub ahead of print].

Iwaniec T, et al. Clinical utility of automated chemiluminescent antiphospholipid antibody assay. Thromb Res 2015 Nov;136(5):1033-9.

*Keeling D, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012 Apr;157(1):47-58.

Mekinian A, et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev 2017 Jul;16(7):730-734.

Merashli M, et al. Antiphospholipid syndrome: an update. Eur J Clin Invest 2015 Jun;45(6):653-62..

Meroni PL, et al. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014;16(2):209.

Pengo V, et al. Laboratory testing for antiphospholipid syndrome. Int J Lab Hematol 2016 May;38 Suppl 1:27-31.

Saccone G, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol May;216(5):525.e1-525.e12.

Santos TDS, et al. Antiphospholipid syndrome and recurrent miscarriage: a systematic review and meta-analysis. J Reprod Immunol 2017 Sept;123:78-87.

Whitaker KL. Antiphospholipid antibody syndrome: the difficulties of diagnosis. JAAPA 2017 Dec;30(12):10-14.

*key article

KEY WORDS:

Hughes syndrome, lupus anticoagulant (LA) syndrome, “sticky blood syndrome”, Antiphospholipid Syndrome, Antiprothrombin antibodies

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently no National Coverage Determination (NCD) or Local Coverage Determination (LCD) for Antiprothrombin Antibody testing.